|Bid||0.00 x 1300|
|Ask||3.20 x 1000|
|Day's Range||1.96 - 2.14|
|52 Week Range||1.62 - 10.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
OpGen, Inc. (OPGN) today announced that it has negotiated modifications related to its $1,000,000 Second Amended and Restated Senior Secured Promissory Note (the “Note”), dated June 28, 2017, to extend the maturity of the note and to pay accrued interest through the issuance of shares of common stock. The Note is issued to Merck Global Health Innovation Fund, LLC (Merck GHI).
OpGen, Inc. (OPGN) today announced the presentation of data from the first phase of its Acuitas® urine clinical verification study demonstrating high accuracy in predicting antibiotic resistance in urine specimens. In the study, remnant urine specimens were provided by Intermountain Healthcare and Beth Israel Deaconess Medical Center and were tested with the Acuitas AMR Gene Panel u5.47 (Research Use Only ‘RUO’) to detect 5 pathogens and 47 resistance genes common to urinary tract infections. From the resulting genetic data, the Acuitas Lighthouse® Software (RUO) then predicted antibiotic resistance with greater than 90% accuracy.
GAITHERSBURG, Md., June 05, 2018-- OpGen, Inc. today announced that data on its Acuitas ® AMR Gene Panel u5.47 and Acuitas Lighthouse ® Knowledgebase will be presented at ASM Microbe 2018 being held June ...
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
Revenue increases 10% to $0.8 million, net loss decreases 39% to $3.0 million. Conference call begins at 4:30 p.m. Eastern time today. GAITHERSBURG, Md., May 08, 2018-- OpGen, Inc. today reported financial ...
GAITHERSBURG, Md., May 01, 2018-- OpGen, Inc. announced today that the Company will report financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Tuesday, ...
GAITHERSBURG, Md., April 24, 2018-- OpGen, Inc. today announced that it has presented analytical validation results for the Acuitas ® AMR Gene Panel u5.47 for detection of multi-drug resistant pathogens ...
Newly public NeuroOne (NMTC) could be one of these movers in 2018 as they plan to file their first FDA medical device submission in the upcoming months. This technology addresses a large market opportunity and could support multiples of upside.
GAITHERSBURG, Md., April 19, 2018-- OpGen, Inc. OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification ...
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / OpGen, Inc. (NASDAQ: OPGN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern Time. To listen ...
Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN ). If you want access ...
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
OpGen Inc. is back in compliance with Nasdaq's rules, but CEO Evan Jones says the Gaithersburg biotech must do a better job helping the market recognize its value. The molecular diagnostics company (OPGN) staved off its third delisting threat in the last year after making a number of financial moves, including a 1-for-25 reverse stock split to help increase its share price above Nasdaq's $1-per-share minimum, one of the issues that put OpGen at risk. OpGen also priced a $12 million public offering Friday, selling 3.6 million units comprising one share of common stock and one common warrant to purchase one-half share of common stock at $3.25 each.
Evan Jones is the CEO of OpGen Inc (NASDAQ:OPGN), which has recently grown to a market capitalization of $9.07M. Understanding how CEOs are incentivised to run and grow their companyRead More...